Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jade Ghosn

Showing results (131-140 of 267) with videos related to

Pageof 27
Sort By:
Substance Use & Misuse|December 5, 2025
Clinical and Socio-Demographic Characteristics Associated with the Severity of Chemsex PracticeSibylle Mauries, Zélie Julia, David Duroy, et al.
Antiviral Therapy|February 6, 2004
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individualsClaudine Duvivier, Astriti Myrto, Anne-Geneviève Marcelin, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2004
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapyMarc Wirden, Constance Delaugerre, Anne Genevieve Marcelin, et al.
Plos One|August 17, 2017
Detectable HIV-RNA in semen of HIV controllersMarie-Laure Chaix, Faroudy Boufassa, Candice Meyzer, et al.
The Journal of Antimicrobial Chemotherapy|September 28, 2025
How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?Marie Gilbert, Valentine Marie Ferré, Romane Guilbaud, et al.
Journal of Clinical Virology Plus|March 9, 2022
Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patientsBernadette Crescenzo-Chaigne, Sylvie Behillil, Vincent Enouf, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2012
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapyMarie-Laure Chaix, Remonie Seng, Pierre Frange, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Evaluation of rapid progressors in HIV infection as an extreme phenotypeAshley D Olson, Marguerite Guiguet, Robert Zangerle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2024
Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective StudyVéronique Joly, Valentine M Ferré, Quentin Le Hingrat, et al.
Hepatology (Baltimore, Md.)|November 11, 2010
Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG studyLionel Piroth, Christine Larsen, Christine Binquet, et al.
Pageof 27

Showing results (131-140 of 267) with videos related to

Sort By:
Pageof 27
Substance Use & Misuse|December 5, 2025
Clinical and Socio-Demographic Characteristics Associated with the Severity of Chemsex PracticeSibylle Mauries, Zélie Julia, David Duroy, et al.
Antiviral Therapy|February 6, 2004
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individualsClaudine Duvivier, Astriti Myrto, Anne-Geneviève Marcelin, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2004
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapyMarc Wirden, Constance Delaugerre, Anne Genevieve Marcelin, et al.
Plos One|August 17, 2017
Detectable HIV-RNA in semen of HIV controllersMarie-Laure Chaix, Faroudy Boufassa, Candice Meyzer, et al.
The Journal of Antimicrobial Chemotherapy|September 28, 2025
How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy?Marie Gilbert, Valentine Marie Ferré, Romane Guilbaud, et al.
Journal of Clinical Virology Plus|March 9, 2022
Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patientsBernadette Crescenzo-Chaigne, Sylvie Behillil, Vincent Enouf, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 11, 2012
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapyMarie-Laure Chaix, Remonie Seng, Pierre Frange, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 30, 2014
Evaluation of rapid progressors in HIV infection as an extreme phenotypeAshley D Olson, Marguerite Guiguet, Robert Zangerle, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2024
Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective StudyVéronique Joly, Valentine M Ferré, Quentin Le Hingrat, et al.
Hepatology (Baltimore, Md.)|November 11, 2010
Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG studyLionel Piroth, Christine Larsen, Christine Binquet, et al.
Pageof 27